Keep calm and CAR-T on?

Lori, Greg and Tyler discuss last week’s ⁠call for a class-wide box warning⁠ on all commercial CAR T therapies, while investigations are ongoing into ⁠cases of secondary malignancies⁠. How do we approach this ⁠balancing act⁠ of treatment and side effects?

Almost 30,000 patients have now been treated with CAR-T cell therapies since the first approval in 2017. In November 2023, the FDA ⁠launched a probe⁠ into malignancies caused by CAR T therapies, and just last week the agency ⁠called for a class-wide box warning⁠ on all commercial CAR T therapies with ongoing investigations into ⁠cases of secondary malignancies⁠. How do we approach this ⁠balancing act⁠ of treatment and side effects?

Also this week: IPOs march on with ⁠ArriVent, CG Oncology⁠, ⁠Alto Neuroscience, Fractyl Health⁠; and what’s happening re: Congressional Budget Office, Centers for Medicare & Medicaid Services and drug pricing.

Join BioSpace’s Lori Ellis, Greg Slabodkin and Tyler Patchen as they discuss.

Lori Ellis is the head of insights at BioSpace, providing industry analysis as well as paid custom content for BioSpace clients. Her current focus is on the ever-evolving impact of technology on the pharmaceutical industry. You can reach her at lori.ellis@biospace.com. Follow her on LinkedIn.

Greg Slabodkin is the News Editor at BioSpace. You can reach him at greg.slabodkin@biospace.com. Follow him on LinkedIn.    

Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn.


> Listen on Spotify

> Listen on Apple podcasts

> Listen on Amazon Music

> Listen on iheart

Lori Ellis is the Head of Insights at BioSpace. She analyzes and comments on industry trends for BioSpace and clients. Her current focus is on the ever-evolving impact of technology on the pharmaceutical industry. You can reach her at lori.ellis@biospace.com. Follow her on LinkedIn.
Greg is a seasoned editor/writer who has covered the healthcare, life sciences and medical device industries for several tech trade publications. Follow him on LinkedIn.
Tyler Patchen is a freelance writer based in Alabama. He was formerly staff writer at BioSpace. You can reach him at tpatchen94@gmail.com.
MORE ON THIS TOPIC